PepTalk’s Antibody Discovery & Engineering pipeline offers a forum for protein scientists who are working to quickly and efficiently discover and develop differentiated biotherapeutics for unmet medical needs. For 2024, the pipeline presents the two-part Intelligent Antibody Discovery program, with Part 1 focused on methods and technologies that offer predictive insight into function, binding and developability in support of improved candidate selection, and Part 2 considering current progress in integrating machine learning into discovery and engineering workflows.

January 16-17

Intelligent Antibody Discovery: Part One

January 18-19

Intelligent Antibody Discovery: Part Two


Peter M. Tessier, PhD

Predicting Antibody Developability at the Discovery Stage
Peter M. Tessier, PhD, Albert M. Mattocks Professor, Pharmaceutical Sciences & Chemical Engineering, University of Michigan

Chris Bahl, PhD

Better Medicines, Created Rapidly through de novo Protein Design
Chris Bahl, PhD, CSO and Co-Founder, AI Proteins

Benjamin J. Hackel, PhD

De novo Design of Miniprotein Ligand Scaffolds for Molecularly Targeted Therapy
Benjamin J. Hackel, PhD, Professor, Chemical Engineering & Materials Science, University of Minnesota

If you are working in the following areas join the PepTalk community: 

  • Antibody Discovery
  • Antibody Engineering
  • Antibody Technologies
  • Biologics Development
  • Biotherapeutics Development
  • Cellular Engineering
  • Development
  • Protein Engineering
  • Protein Sciences
  • Regulatory Affairs
  • Research